Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (141-150 of 199) with videos related to

Pageof 20
Sort By:
Cell & Bioscience|March 17, 2015
Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cellsJinfeng Suo, Daniel Medina, Sabrina Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersBhuvanesh Dave, Ilenia Migliaccio, M Carolina Gutierrez, et al.
Nucleic Acids Research|January 14, 2020
Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activityFabio Stossi, Radhika D Dandekar, Maureen G Mancini, et al.
Breast Cancer Research : BCR|November 30, 2011
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivationYen-Chao Wang, Gladys Morrison, Ryan Gillihan, et al.
Breast Cancer Research and Treatment|April 22, 2008
Molecular profiles of progesterone receptor loss in human breast tumorsChad J Creighton, C Kent Osborne, Marc J van de Vijver, et al.
Nature Communications|August 8, 2014
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancersJamunarani Veeraraghavan, Ying Tan, Xi-Xi Cao, et al.
ACS Nano|June 4, 2014
Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshellsCiceron Ayala-Orozco, Cordula Urban, Mark W Knight, et al.
British Journal of Pharmacology|February 18, 2025
Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2-positive breast cancerNoor Mazin Abdulkareem, Raksha Bhat, Micah Castillo, et al.
Breast Cancer Research : BCR|June 24, 2010
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerChad J Creighton, Xiaoyong Fu, Bryan T Hennessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancerChirayu Shah, Todd W Miller, Shelby K Wyatt, et al.
Pageof 20

Showing results (141-150 of 199) with videos related to

Sort By:
Pageof 20
Cell & Bioscience|March 17, 2015
Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cellsJinfeng Suo, Daniel Medina, Sabrina Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersBhuvanesh Dave, Ilenia Migliaccio, M Carolina Gutierrez, et al.
Nucleic Acids Research|January 14, 2020
Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activityFabio Stossi, Radhika D Dandekar, Maureen G Mancini, et al.
Breast Cancer Research : BCR|November 30, 2011
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivationYen-Chao Wang, Gladys Morrison, Ryan Gillihan, et al.
Breast Cancer Research and Treatment|April 22, 2008
Molecular profiles of progesterone receptor loss in human breast tumorsChad J Creighton, C Kent Osborne, Marc J van de Vijver, et al.
Nature Communications|August 8, 2014
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancersJamunarani Veeraraghavan, Ying Tan, Xi-Xi Cao, et al.
ACS Nano|June 4, 2014
Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshellsCiceron Ayala-Orozco, Cordula Urban, Mark W Knight, et al.
British Journal of Pharmacology|February 18, 2025
Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2-positive breast cancerNoor Mazin Abdulkareem, Raksha Bhat, Micah Castillo, et al.
Breast Cancer Research : BCR|June 24, 2010
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerChad J Creighton, Xiaoyong Fu, Bryan T Hennessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancerChirayu Shah, Todd W Miller, Shelby K Wyatt, et al.
Pageof 20